Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$30.59 USD
-0.16 (-0.52%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $30.59 0.00 (0.00%) 5:26 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for Apellis Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 352 | 553 | 702 | 879 | 352 |
Receivables | 206 | 8 | 10 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 146 | 86 | 16 | 0 | 0 |
Other Current Assets | 61 | 73 | 96 | 38 | 21 |
Total Current Assets | 766 | 720 | 824 | 917 | 373 |
Net Property & Equipment | 4 | 6 | 6 | 7 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 16 | 32 | 19 | 0 |
Total Assets | 789 | 760 | 882 | 961 | 389 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 38 | 37 | 17 | 8 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 128 | 95 | 103 | 112 | 55 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 76 | 30 | 8 | 4 | 0 |
Total Current Liabilities | 248 | 168 | 132 | 128 | 66 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 93 | 93 | 189 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 359 | 143 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 242 | 316 | 345 | 254 | 135 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 594 | 590 | 683 | 756 | 355 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 3,036 | 2,480 | 1,857 | 1,131 | 616 |
Retained Earnings | -2,837 | -2,309 | -1,657 | -926 | -581 |
Other Equity | -4 | -1 | -2 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 195 | 170 | 199 | 205 | 34 |
Total Liabilities & Shareholder's Equity | 789 | 760 | 882 | 961 | 389 |
Total Common Equity | 195 | 170 | 199 | 205 | 34 |
Shares Outstanding | 118.50 | 110.50 | 97.50 | 75.70 | 74.80 |
Book Value Per Share | 1.64 | 1.54 | 2.04 | 2.70 | 0.46 |
Fiscal Year End for Apellis Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 361 | 327 | 352 | 454 | 617 |
Receivables | 304 | 268 | 206 | 169 | 111 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 153 | 161 | 146 | 99 | 103 |
Other Current Assets | 41 | 55 | 61 | 75 | 61 |
Total Current Assets | 860 | 811 | 766 | 797 | 893 |
Net Property & Equipment | 4 | 4 | 4 | 5 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 23 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 904 | 832 | 789 | 818 | 916 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 38 | 27 | 38 | 18 | 28 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 123 | 101 | 128 | 117 | 98 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 81 | 76 | 45 | 44 |
Total Current Liabilities | 169 | 215 | 248 | 186 | 175 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 93 | 93 | 93 | 93 | 93 |
Long-Term Debt | 364 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 242 | 296 | 290 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 640 | 565 | 594 | 586 | 570 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 3,209 | 3,174 | 3,036 | 2,982 | 2,955 |
Retained Earnings | -2,942 | -2,904 | -2,837 | -2,749 | -2,609 |
Other Equity | -3 | -4 | -4 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 264 | 267 | 195 | 232 | 345 |
Total Liabilities & Shareholder's Equity | 904 | 832 | 789 | 818 | 916 |
Total Common Equity | 264 | 267 | 195 | 232 | 345 |
Shares Outstanding | 121.70 | 121.20 | 118.50 | 118.50 | 117.70 |
Book Value Per Share | 2.17 | 2.20 | 1.64 | 1.96 | 2.93 |